Literature DB >> 8722843

Role of azoles in antifungal therapy.

C A Kauffman1.   

Abstract

The addition of itraconazole and fluconazole to the antifungal armamentarium has resulted in less toxic, easily administered therapy for both endemic and opportunistic mycoses. Itraconazole has become the treatment of choice for most patients with mild-to-moderate histoplasmosis, blastomycosis, and sporotrichosis. Coccidioidomycosis is effectively treated with either itraconazole or fluconazole; fluconazole has become the drug of choice for the treatment of coccidioidal meningitis. In several large cooperative trials, fluconazole has been shown to have a useful role in the treatment of patients with candidemia, localized forms of mucocutaneous and visceral candidiasis, and cryptococcal meningitis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8722843     DOI: 10.1093/clinids/22.supplement_2.s148

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

1.  Emerging Issues in Nosocomial Fungal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

2.  Compartmental pharmacokinetics and tissue drug distribution of the pradimicin derivative BMS 181184 in rabbits.

Authors:  A H Groll; T Sein; V Petraitis; R Petraitiene; D Callender; C E Gonzalez; N Giri; J Bacher; S Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

3.  Invasive fungal infections in Canada from 1992 to 1994.

Authors:  L Nicolle; C Rotstein; A Bourgault; G St-Germain; G Garber
Journal:  Can J Infect Dis       Date:  1998-11

Review 4.  Experimental oral candidiasis in animal models.

Authors:  Y H Samaranayake; L P Samaranayake
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

5.  In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum.

Authors:  R K Li; M A Ciblak; N Nordoff; L Pasarell; D W Warnock; M R McGinnis
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 6.  Antifungal agents in the 1990s. Current status and future developments.

Authors:  C A Kauffman; P L Carver
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 7.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

8.  Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Marina McIver; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 9.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

10.  Fungal Infections of the Lung.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.